American Century Companies’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
Other funds holding ALLO
P
TGA
VCM
American Century Companies's ALLO Position: Q1 2026 in Review
American Century Companies opened a new position in Allogene Therapeutics (ALLO) in Q1 2026: 50,228 shares worth $123K. The stake represents ﹤0.01% of the portfolio and ranks #2762 among its holdings. This is a return to the name: American Century Companies previously reported a position in ALLO as recently as Q4 2024.
American Century Companies first reported a position in ALLO in Q3 2022 and has held it in 11 quarters since. The position peaked at $558K in Q3 2024. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.
- American Century Companies held 50,228 shares of Allogene Therapeutics worth $123K as of Q1 2026.
- Allogene Therapeutics was a new American Century Companies position in Q1 2026.
- Allogene Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q1 2026, its #2762 holding.
- American Century Companies first reported a position in Allogene Therapeutics in Q3 2022 and has held it in 11 quarters since.
- American Century Companies's Allogene Therapeutics position peaked at $558K in Q3 2024.
- 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.
Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.